Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Opsoclonus myoclonus syndrome (OMS) is a rare neuroinflammatory disease of paraneoplastic, parainfectious or idiopathic origin, characterized by opsoclonus, myoclonus, ataxia, and behavioral and sleep disorders.
Biomarker and diagnostic research for opsoclonus-myoclonus syndrome has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
177 publications have been identified in PubMed for opsoclonus-myoclonus syndrome. Kisho has analyzed 72 by research type. Research spans Review / Meta-Analysis (38%), Case Report / Case Series (38%), and Epidemiology / Natural History (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 27 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 2:54 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Genetic and Rare Diseases Info Center
38%
Patient case studies | 27 | 38% |
Disease patterns and progression | 7 | 10% |
Laboratory research | 6 | 8% |
Testing and diagnosis research | 3 | 4% |
Other research | 2 | 3% |
Voirin M (2026). [PMID: 41270903](https://pubmed.ncbi.nlm.nih.gov/41270903/). *Lab Invest*. [Basic Science / Preclinical]
Jannot L (2026). [PMID: 41936749](https://pubmed.ncbi.nlm.nih.gov/41936749/). *Transl Oncol*. [Review / Meta-Analysis]
Ibukuro M (2026). [PMID: 41093557](https://pubmed.ncbi.nlm.nih.gov/41093557/). *Intern Med*. [Case Report / Case Series]
Shirota S (2026). [PMID: 41629114](https://pubmed.ncbi.nlm.nih.gov/41629114/). *BMJ case reports*. [Case Report / Case Series]
Olivé-Cirera G (2026). [PMID: 41499722](https://pubmed.ncbi.nlm.nih.gov/41499722/). *Neurol Neuroimmunol Neuroinflamm*. [Basic Science / Preclinical]
Kuchalska K (2026). [PMID: 41979173](https://pubmed.ncbi.nlm.nih.gov/41979173/). *Pediatr Hematol Oncol*. [Epidemiology / Natural History]
Arduç Akçay A (2026). [PMID: 41871563](https://pubmed.ncbi.nlm.nih.gov/41871563/). *Turk J Pediatr*. [Epidemiology / Natural History]
Chen Y (2026). [PMID: 41894019](https://pubmed.ncbi.nlm.nih.gov/41894019/). *J Neurol*. [Review / Meta-Analysis]
Guijarro-Castro C (2025). [PMID: 38387776](https://pubmed.ncbi.nlm.nih.gov/38387776/). *Neurologia (Engl Ed)*. [Other]
Li DX (2025). [PMID: 41058784](https://pubmed.ncbi.nlm.nih.gov/41058784/). *Cureus*. [Case Report / Case Series]